When researchers successfully reprogrammed human somatic cells into induced pluripotent stem cells (iPSCs), it promised a revolution in medicine: the ability to grow a personalized, "biopsy-equivalent" model of any patient's internal organs in a laboratory dish.
However, an elegant but frustrating biological bottleneck has emerged. While scientists can reliably direct stem cells to adopt the identity of specific lineages—turning them into beating heart cells, firing neurons, or insulin-secreting islets—these engineered cells almost universally stall at an embryonic or fetal stage of development. This discrepancy between the chronological age of the donor and the developmental age of the derived cells is known as the cellular maturation gap.
To understand why this gap occurs and why it fundamentally limits our ability to model human disease, we must look at how cells mature structurally, metabolically, and transcriptomically.
The Anatomy of Immaturity
An adult cell is not merely an embryonic cell that has stopped dividing; it is a highly specialized, structurally complex machine optimized for high-performance physiology. In vitro differentiation protocols, however, typically yield cells that resemble neonatal or prenatal tissue. This immaturity manifests across three primary axes: structural organization, metabolic programming, and transcriptomic identity.
1. Structural Disorganization
In mature tissues, cellular architecture dictates function. For example, adult cardiomyocytes (heart muscle cells) are large, elongated, and packed with highly organized contractile units called sarcomeres. They also possess specialized membrane invaginations known as T-tubules, which are essential for rapid calcium handling and synchronized contractions.
As reviewed by Li et al., stem-cell-derived cardiomyocytes typically retain a fetal-like state characterized by small, rounded shapes, disorganized sarcomeres, and a complete lack of T-tubules. This structural deficit causes the cells to exhibit weak mechanical output and spontaneous, erratic beating rather than coordinated, high-force contractions (Poon et al.).
2. Metabolic Mismatch
Embryos and adults power their cells differently. Fetal tissues exist in a relatively hypoxic uterine environment and rely primarily on glycolysis—the rapid but inefficient breakdown of glucose—for energy. As an organism matures postnatally, its cells undergo a metabolic switch. Adult heart cells, for instance, shift almost entirely to fatty acid oxidation to meet their immense energetic demands.
Funakoshi et al. demonstrated that standard lab-grown cardiomyocytes remain trapped in this fetal glycolytic state. This metabolic immaturity prevents the cells from generating the high energy output required to mimic adult tissue engineering and functional organ performance.
3. Transcriptomic and Isoform Stagnation
The maturation gap is ultimately governed by gene expression networks. During natural development, cells undergo precise "isoform switching," replacing embryonic proteins with adult variants. A classic example is the transition from the fetal troponin isoform ($TNNI1$) to the adult isoform ($TNNI3$) in the heart.
Current differentiation protocols frequently fail to trigger these genetic switches. The authors of a study on hepatocyte-like cells (HLCs) found that while stem-cell-derived liver cells express broad hepatic markers, they remain transcriptomically immature compared to primary human hepatocytes, retaining suboptimal gene networks (Shi et al.). Similarly, stem-cell-derived pancreatic islets remain transcriptionally closer to fetal tissue than adult tissue, lacking immediate, robust glucose responsiveness upon generation (Usama et al.).
[Somatic Cell] ──(Reprogramming)──> [iPSC] ──(Differentiation)──> [Fetal-State Cell]
│
[MATURATION GAP]
▼
[Adult-State Cell]
Why the Gap Confounds Disease Modeling
The cellular maturation gap is not just a theoretical problem; it severely compromises our ability to model adult-onset diseases.
Many of the most devastating human conditions—such as Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, and various cardiomyopathies—are chronic, degenerative disorders that take decades to manifest. Their onset is driven by the cumulative toll of aging, epigenetic drift, and prolonged cellular stress.
When researchers attempt to model these conditions using iPSC-derived lines, they are essentially trying to study a geriatric disease in a newborn cell:
- Neurodegeneration: As noted by Baxi et al., the developmental immaturity of stem-cell-derived motor neurons means they lack the cumulative aging-related stressors critical to ALS onset. Similarly, Zheng et al. point out that generating immature glial cells hinders the accurate modeling of late-onset neurodegenerative pathologies that emerge in aged populations.
- Cardiac Pathology: Modeling conditions like hypertrophic or dilated cardiomyopathy requires observing how a cell responds to chronic workload or proteotoxic stress. Because patient-derived cardiomyocytes resemble fetal cells, they often appear completely healthy under baseline laboratory conditions, masking pathogenic phenotypes that only emerge under the physiological stress of a fully developed adult organ (McDermott‐Roe et al.; Li et al.).
Furthermore, three-dimensional models like brain organoids frequently hit a developmental plateau. As argued by Yi Eve Sun, while 3D organoids capture complex spatial architecture, they remain restricted to fetal developmental stages, lacking the mature epigenetic markers and synaptic densities found in adult brain tissue.
Bridging the Gap
Why do cells stall in vitro? In an embryo, cellular maturation is driven by a dynamic symphony of sequential biochemical signals, physical forces (such as blood shear stress and mechanical stretching), and complex positional cues from surrounding tissues. Standard laboratory environments—often consisting of flat plastic dishes and static liquid media—completely lack this context (Briggs et al.).
To overcome this, researchers are developing strategies to force lab-grown cells past their developmental roadblocks:
- Replicating the Niche: Standard culture media often leave cells transcriptomically underdeveloped. For example, Bruna Paulsen demonstrated that co-culturing immature oocytes with stem-cell-derived ovarian support cells drastically improves nuclear maturation and transcriptomic resemblance to native, in vivo-matured cells.
- Metabolic and Chemical Forcing: Rather than relying solely on genetic transcription factors, researchers are using metabolic interventions—such as forcing cells to utilize fatty acids instead of glucose—to drive structural maturation and adult-like protein isoform transitions (Funakoshi et al.).
- In Vivo Maturation: Currently, one of the most reliable ways to achieve full maturation is to let nature do the work. In pancreatic islet therapy, stem-cell-derived islets are transplanted into a living host, where they undergo an extended period of vascularization and environmental exposure to achieve adult-like glucose regulation (Usama et al.).
Understanding and systematically closing the cellular maturation gap is the next major frontier in stem cell biology. Only by guiding engineered cells across this developmental divide can we create high-fidelity models that truly mirror human physiology and disease.